- All-RNA gene writing for T cells (RetroT): Utilizes human LINE-1 machinery to drive programmable, site-specific integration of multi-kb payloads, without DSBs, supporting a superior genomic safety profile.
- Successful genetic delivery of CART constructs to T cells
CAMBRIDGE, Mass., Oct. 29, 2025 -- CREATE Medicines, Inc. (formerly Myeloid Therapeutics) today announced new preclinical data for RetroT, the company's fully RNA-encoded, site-specific gene-integration system, presented at the Cold Spring Harbor Laboratory Meeting on Immune Engineering & Cellular Immunotherapy. The results highlight precise integration of therapeutic payloads without double-strand DNA breaks, viral vectors, or DNA templates, supporting a path to safer, scalable in vivo cell engineering.
"RetroT reframes what's possible, a purely RNA-based system that programs T cells in vivo with site-specific, durable gene insertion while maintaining the flexibility to re-dose," said Robert Hofmeister, PhD, Chief Scientific Officer of CREATE Medicines. "When combined with our targeted LNP delivery and human-validated mRNA platform, RetroT provides a direct and scalable path to clinical proof of concept."
By harnessing the natural mobility of the LINE-1 retrotransposon and a CRISPR-based nickase, the results demonstrate that RetroT achieves site-specific integration of genetic payloads into immune cells. This approach has the potential to transform precision in vivo gene editing by reducing off-target effects and genotoxicity associated with traditional CRISPR/Cas9 methods.
In the presented study, CREATE Medicines used RetroT to successfully insert a CD19-CAR transgene into human T cells. RetroT uses the LINE-1 retrotransposon, the only active "jumping gene" in the human genome, to integrate genetic payloads without double-strand DNA breaks, viral vectors, or DNA payloads. RetroT engineered T cells show full functionality and target-specific cytotoxicity while preserving cell fitness and phenotype. Sequencing confirmed precise integration with no detectable off-target effects, partial insertions, or genomic scars.
Additional background on RetroT is available in the peer-reviewed publication "CRISPR-Enabled Autonomous Transposable Element (CREATE) for RNA-based gene editing and delivery," published in EMBO Reports in January (Wang et al., EMBO Rep (2025)26:1062–1083).
CREATE Medicines continues to advance its multi-immune programming platform, which enables selective programming of T cells, myeloid cells, and NK cells directly within the body. The company's pipeline includes next-generation in vivo CAR therapies for solid tumors and autoimmune diseases, supported by a validated LNP delivery platform and proprietary RNA engineering.
Presentation Details
- Title: CRISPR Enabled Autonomous Transposable Element (CREATE), an All-RNA Platform to Engineer T Cells
- Authors: Meghan Harris, Bianca Lavayen, Yuxiao Wang, Daniel Getts, Robert Hofmeister, Philippe Kieffer-Kwon
- Meeting: Cold Spring Harbor Laboratory Meeting on Immune Engineering & Cellular Immunotherapy
- Poster date and time: October 29, 2025, 7:30 – 10:30 PM, Poster #57
- Location: Cold Spring Harbor, New York
- Meeting program: https://meetings.cshl.edu/meetings.aspx?meet=IMMENG
About CREATE Medicines
CREATE Medicines (formerly Myeloid Therapeutics) is a clinical-stage biotech pioneering in vivo multi-immune programming. Its proprietary mRNA-LNP platform directly programs immune cells inside the body to deliver scalable, repeat-dose, off-the-shelf immunotherapies. With proven human validation and next-generation RNA technology, CREATE is advancing a pipeline of in vivo CAR therapies to transform outcomes in cancer, autoimmunity, and fibrosis.
For more, visit createmedicines.com. Follow us on LinkedIn and X (Twitter).
Business Development: partnering@createmedicines.com
This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.
